Glioblastomas (GBMs) contain highly tumorigenic, self-renewing populations of stem/initiating cells (GSCs) that contribute to tumor propagation and treatment resistance. However, our knowledge of the specific signaling pathways that regulate GSCs is limited. The MET tyrosine kinase is known to stimulate the survival, proliferation, and invasion of various cancers including GBM. Here, we identified a distinct fraction of cells expressing a high level of MET in human primary GBM specimens that were preferentially localized in perivascular regions of human GBM biopsy tissues and were found to be highly clonogenic, tumorigenic, and resistant to radiation. Inhibition of MET signaling in GSCs disrupted tumor growth and invasiveness both in vitro and in vivo, suggesting that MET activation is required for GSCs. Together, our findings indicate that MET activation in GBM is a functional requisite for the cancer stem cell phenotype and a promising therapeutic target.
INTRODUCTION
Glioblastoma multiforme (GBM) is the most common and lethal primary brain tumor with a median survival of 14.6 months despite maximal therapy (1) . As included in classification criteria for GBMs, excessive and unstable blood vessel formation and tumor necrosis associated with hypoxia are key pathological characteristics of GBMs (2) .
GBMs heavily infiltrate into the neighboring brain parenchyma and are almost uniformly resistant to standard therapeutic regimes such as irradiation and chemotherapy (3) .
These biological characteristics of GBMs are major reasons of lethality and need to be targeted for therapy.
Cancer stem cell (CSC) hypothesis posits that a subpopulation of cancer cells is highly enriched with tumorigenic potential (3) (4) (5) (6) (7) . Compared to bulk tumor cells, GSCs survive better against irradiation and chemotherapies, thereby contributing to therapeutic resistance and tumor recurrence (8, 9) . In addition, GSCs frequently reside in perivascular and hypoxic regions, actively promoting angiogenesis and facilitating the survival in harsh environment (10) (11) (12) . However, the underlying molecular pathways that govern these processes in GSCs are poorly understood.
The MET receptor tyrosine kinase (RTK) regulates cell growth and motility. Hepatocyte growth factor (HGF)/Scatter factor (SF) is a cognate ligand for MET signaling (13, 14) .
MET pathway activation induces glioma cell proliferation, survival, and migration (15, 16) . We and others reported that MET overexpression is associated with poor prognosis and tumor invasiveness in GBM patients (17, 18). Large-scale genomic studies confirmed frequent MET pathway activation and genomic amplification of MET in GBMs, indicating that aberrant activation of MET is an important genetic event in GBMs (19-21).
As hypoxia directly induces MET expression and HGF induces expression of vascular endothelial growth factor (VEGF) in glioma cells, MET signaling may be particularly important for tumor cell survival in hypoxia and co-option with angiogenesis (15, 22, 23 ).
In addition, it was reported that MET signaling is a key mechanism to maintain stem cell niche in brain (24) . A recent study reported that MET signaling enhances GSC populations, suggesting a link between MET signaling and GSCs (25). The precise roles of MET signaling operated in GSCs, however, remain unclear (25).
Based on this background, we hypothesized that MET signaling promotes self-renewal and therapeutic resistance of GSCs. By extensive in vivo and in vitro studies utilizing a large number of freshly isolated patient-derived GBM cells, we provide evidence suggesting that MET signaling plays critical roles in GSC maintenance, migration, and resistance to radiation. 
MATERIALS AND METHODS

Isolation of primary GBM cells and establishment of short-term cultured GSCs.
Following informed consent, glioblastoma specimens were obtained from patients undergoing surgery at the Samsung Medical Center in accordance with the Institutional Review Boards. Tumor specimens were classified as GBM based on World Health Organization (WHO) criteria by examination of pathologists (2) . Tumor specimens were enzymatically dissociated into single cells and cultured, following the procedures previously reported (26, 27) .
FACS analysis and sorting
Patient GBM-derived tumor cells were dissociated into single cells and labeled with the following antibodies; anti-MET (R&D systems), anti-CD133-PE (Miltenyi Biotec), anti-CD15-FITC (MMA clone, BD)(28). For MET staining and sorting, one million cells were labeled with 2 μg of antibodies at 4 0 C for 10 min. Antibodies against mouse immunoglobulin conjugated to PE or FITC were used as antibody isotype controls (BD).
The stained cells were analyzed on the FACS Aria (BD). Cell Quest Acquisition and Analysis software (BD) was used to acquire and quantify the fluorescence signal distributions and intensities from individual cells.
Antibodies
The following antibodies were used as primary antibodies: MET (Zymed and Santa Cruz for detection of total MET protein; Cell Signaling for detection of phosphorylated MET proteins), Nestin, Sox2 (R&D systems), GFAP (Dako), TuJ1 (Covance), O4 (Chemicon), α-tubulin and β-actin (Sigma), and AKT and Erk (Cell Signaling). Tumor cells were dissociated into single-cell suspensions, sorted for MET expression, and then plated into 96-well plates with various seeding densities (1 to 500 cells per well depending on the experiment, >30 wells for each condition). mice by using a stereotactic device (Kopf instruments) (coordinates: 2 mm anterior, 2 mm lateral, 2.5 mm depth from the dura). Mice with neurological signs were killed for the analysis of tumor histology and immunohistochemistry. All mice experiments were performed according to the guidelines of the Animal Use and Care Committees.
Tumorsphere forming limiting dilution assay
Intracranial tumor cell injection into NOD/SCID
In vivo delivery of MET siRNA-polyelectrolyte-micelle complexes
For the conjugation of MET siRNA or non-targeting siRNA with polyethylene glycol 5000 (PEG5K), we followed the procedures as previously described (29). PEG-MET siRNA or PEG-control siRNA (0.5 mg/kg body weight) complexes were delivered through tail vein injections twice a week for four weeks.
Determination of intracranial tumor volumes
To estimate the size of intracranial tumor, we performed immunohistochemical analysis using an anti-human nuclei specific antibody (Chemicon) on the serial brain sections. 
Statistical Analysis
All values are shown as mean ± standard deviation (SD). For group comparison, paired 7 t-test (two group comparison) or ANOVA (more than three group comparison) were used. Kaplan-Meier survival analysis was performed using Prism 4.0 software.
Supplemental Data
Supplemental Data include three tables and nine figures. 
RESULTS
MET-positive tumor cells are preferentially located in perivascular regions of
human GBM specimens and co-express GSC markers.
We reasoned that components of a GSC regulator pathway would be preferentially expressed in perivascular regions and hypoxic edges, the proposed in vivo niches for GSCs (10) . By immunohistochemical analysis using human GBM patient specimens (n=93), we determined the expression patterns and intensities of various growth factor receptors, oncogenes, and stem cell associated proteins.
High frequency of cells positive for MET (more than 10% of tumor cells) in GBM specimens was positively correlated with the shorter progression-free-survival (PFS) and overall survival (OS) of the patients, suggesting a potential role of MET overexpression in malignancy ( Figure 1 A and B) . We also determined whether high expression of MET mRNA in GBM specimens portends poor patient survival by the analysis of The Cancer Genome Atlas (TCGA) database ( Figure S1 ) (19). Patients with high MET mRNA expression have shorter PFS and OS, however, the prognostic value was marginal although significant ( Figure S1 ).
We found that MET protein expression displayed inter-and intratumoral heterogeneity.
Interestingly, cells strongly stained for MET were predominantly located near blood vessels and hypoxic edges ( Figure 1 C and D) . To quantify the proximity between METpositive cells and endothelial cells in primary GBM specimens, we performed dual immunofluorescence for CD31 (endothelial marker) and MET using the frozen sections derived from four GBM patient specimens (Figure 1 E to G). MET-positive cells were located closely to the nearest blood vessels, compared to MET negative cells ( Figure   1G ). In addition, a subset of tumor cells express both GSC enrichment markers CD133/CD15 and MET ( Figure S2 ) (7, 28) .
To obtain more quantitative results, we determined the expression level of MET in the Table S1 ). CD133 and/or CD15 positive cells were enriched (2-to 7-fold) in MET-positive subpopulation compared to the bulk tumor cells.
Conversely, MET-positive cells were enriched in CD133+ or CD15+ populations (Table   S1 ).
To corroborate these findings, we extended our analysis to the previously characterized GSCs derived from human GBM specimens (26, 28). GSCs and their derivatives used in this study are described in supplementary information (Table S2) . We fractionated these short-term cultured GSCs by FACS and performed immunoblot analysis ( Figure   2B ). MET protein was highly expressed in CD133+ (or in CD15+) subpopulations 1 0 compared to the corresponding negative populations in all three GSCs ( Figure 2B ).
Total MET and activated MET protein (Y1234) were preferentially expressed in GSCenriched population compared to GSC-depleted cells ( Figure 2C ). Collectively, these data indicate that MET-positive GBM cells have activated MET signaling and that they significantly overlap with CD133+ and/or CD15+ GBM populations. Table S1 ).
MET
To determine whether MET expression alone can enrich GSCs, we fractionated GBM Figure 5B ). These data suggest that MET but not CD133 is a major determinant for GSC enrichment at least in these GBMs.
MET inhibition decreases the survival, migration, and clonogenicity of GSCs
To interrogate the role of MET in GSC biology, we inhibited MET by short hairpin RNA (shRNA)-mediated knockdown and evaluated its effects on GSCs. To ensure the specific knockdown of MET, we used two independent sequences of shRNA directed against MET mRNA. Both MET shRNA constructs led to a significant reduction in MET protein compared to the non-targeting shRNA control ( Figure S6 ). Figure S7 A and B) . In addition, we performed ex vivo brain slice assays that simulate in vivo migration behavior much better than transwell assays ( Figure S7C ). RFP-expressing GSCs were treated with a chemical MET inhibitor PHA665752 for one day, mixed with GFP-expressing GSCs treated with the vehicle control, and then implanted into the cortex region of 300-micron thick brain slices. Three days after, more than 90% of the migrated cells were GFP-positive, suggesting that MET inhibition decreases glioma cell invasion ( Figure S7 C and D) . Together, these data demonstrate that MET signaling is required for the self-renewal, proliferation, and migration of GSCs. that GSCs preferentially survive radiation and that MET targeting disrupted GSC selfrenewal and clonogenicity, we hypothesized that combination of radiation and MET inhibition in GSCs might be an effective therapeutic approach (9, 34, 35) Figure 7C ). To determine whether MET is directly involved in the clonal re-growth after radiation, we performed the similar clonogenic assays by MET knockdown or treatment with SU11274. Cells with MET inhibition were hardly able to generate spheres after radiation treatment, suggesting that MET inhibition significantly sensitizes GBM cells to radiation ( Figure 7D and Figure S9 ).
In vivo
The above data raise the possibility that MET upregulation after radiation can be a prognostic biomarker for the GBM patients who have received radiation therapy. We acquired 14 matched sets of pre-and post-irradiated (recurrent) tumor specimens from the same GBM patients (Table S3 ). All the patients were diagnosed as de novo primary GBMs and received radiation as a front line therapy after initial surgical resection. We 
DISCUSSION
GSCs remains controversial due to unresolved questions regarding the frequency of these cells, the surface markers by which they can be identified, and the nature of the cell(s) of origin (31, 36) . Previous reports have identified a series of GSC enrichment markers including CD133, CD15, CD44, and A2B5 (7, 28, 37, 38) . Although useful for the prospective isolation of putative GSCs, it is unclear whether these markers have distinct functions pertinent to GSC phenotypes (39, 40) . Therefore, our screening approach in search for a GSC regulator was focused on the protein expression pattern in patient-derived GBM specimens, based on the hypothesis that GSCs are highly enriched in perivascular regions of human GBMs in situ (41) . (33, 49, 50) . Robustness of these biomarkers in GBM needs further validation. For example, genomic MET amplification appears to predict sensitivity to MET inhibition in gastric cancers but less likely in GBMs (33) . A recent paper reported that HGF autocrine status may correlate with MET activity in GBM and predict sensitivity to MET inhibitors (33) . We have determined the correlation between tumor-derived HGF and sensitivity to MET inhibition. Our ongoing studies so far indicated that high HGF-producing GBM cells appear to be more sensitive to MET inhibition compared to the little or no HGFexpressing GBM cells, consistent with the previous report (data not shown) (33) . Further studies are warranted to determine the role of HGF in GSC biology, the effects of HGF targeting on GSC self-renewal and tumorigenicity, and the correlation between HGF and GSC sensitivity to MET inhibition in vivo.
In conclusion, we demonstrate that MET is an enrichment marker for GSCs and a functional requisite for cancer stem phenotype. Not only will these data provide a clue for a more thorough understanding of cancer stem cell biology, but also they further implicate MET as a promising therapeutic target. Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., and CAN-11-3760 the designated name for the each GSC. Actin was used as a loading control. 
